Actively Recruiting
Registry for the Management of Helicobacter Pylori Infection in Shandong Province
Led by Yueyue Li · Updated on 2026-04-02
10000
Participants Needed
2
Research Sites
4 weeks
Total Duration
On this page
Sponsors
Y
Yueyue Li
Lead Sponsor
Q
Qilu Hospital of Shandong University
Collaborating Sponsor
AI-Summary
What this Trial Is About
Helicobacter pylori infection is a widespread gastrointestinal disease affecting about 43.1% of people worldwide. Eradicating this infection is important to reduce risks of gastritis, peptic ulcers, and gastric cancer. Because treatment effectiveness can vary due to factors like antibiotic resistance, smoking, body surface area, genetic differences, patient compliance, and regional differences, this research aims to evaluate various treatment regimens in real-world clinical practice over a long term. This study observes patients receiving Helicobacter pylori treatment regimens prescribed by doctors according to current guidelines and tailored to each patient's situation. It does not involve any intervention or experimental procedure. The study collects data on different treatment strategies, including the use of 14-day high-dose dual therapy and bismuth-containing quadruple therapy, which are recommended first-line treatments. Participants will be monitored through follow-up tests at least six weeks after completing treatment to measure eradication rates. Adverse events are recorded immediately after treatment completion. The study gathers ongoing real-world evidence to understand the effectiveness, safety, and cost-effectiveness of treatments, helping to inform clinical practice. The total participation covers treatment and follow-up over weeks, with no extra interventions beyond regular care.
CONDITIONS
Brief Title
Registry for the Management of Helicobacter Pylori Infection in Shandong Province
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 18 to 80 years, any gender
- Willing to receive H. pylori eradication treatment
- Diagnosed with H. pylori infection by rapid urease test, urea breath test, or histopathological examination
You will not qualify if you...
- Incomplete medical records or missing follow-up test results
- Severe liver failure, kidney failure, or malignant tumors
- Pregnant or breastfeeding women
- Those who refuse to sign informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - At least 6 weeks after treatment completion
Participants who undergo routine care for Helicobacter pylori infection are observed without any additional intervention procedures.
Trial Site Locations
Total: 2 locations
1
Qilu Hospital of Shandong University
Jinan, Shandong, China, 250012
Not Yet Recruiting
2
Qilu Hospital of Shandong University
Jinan, Shandong, China, 250012
Actively Recruiting
Research Team
Y
Yueyue Li
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here